Table 2 5-HT Targeted therapies for weight-loss
5-HT-Targeted Therapy | FDA Approval | FDA Withdrawal | Mechanism of Action | Reason for Withdrawal |
|---|---|---|---|---|
Fenfluramine | 1973 | 1997 | Increase energy expenditure and reduce rate of feeding | Risk for pulmonary hypertension and heart disease |
Dexfenfluramine | 1996 | 1997 | Reduce consumption of palatable food and increase latency to consume | Risk for pulmonary hypertension and heart disease |
Sibutramine | 1997 | 2010 | Inhibit reuptake of 5-HT, reduce food intake, and increase energy expenditure | Increased cardiovascular risk |
Lorcaserin | 2012 | 2020 | 5-HT2C receptor agonist, restore glucose tolerance, insulin sensitivity, and reduce food intake | Weight loss unsustainable, potential carcinogenicity |